Epic Sciences, Station X Link Up to Analyze CTC Data for CDx Development

25 January 2016


NEW YORK (GenomeWeb) – Epic Sciences has announced it will use Station X's GenePool platform as part of data analysis for its collaborations with pharmaceutical companies to develop circulating tumor cell-based companion diagnostics.

GenePool is a web-based software service that allows researchers to analyze and share data. The software is pre-loaded with standard clinical reporting capabilities for incidental findings and tumor profiling, but is also customizable, Station X said in a statement.

"Station X delivers a sophisticated data management and collaboration platform that is allowing us to deliver on our strategy to develop a robust commercial platform with a strong and diverse pipeline of diagnostic and companion diagnostic products," Mark Landers, Director of Genomics at Epic Sciences, said in a statement. The firm noted it is developing companion diagnostics in partnership with pharmaceutical companies in more than 50 active clinical trials.

The deal comes as San Francisco-based Station X begins to align itself with firms offering liquid biopsy technology and services. Last month, the firm announced a partnership with Circulogene.

For Epic Sciences, the announcement comes on the heels of a partnership with the University of Pennsylvania to find biomarkers using CTC technology, announced in November 2015, and CAP accreditation for its San Diego laboratory earlier this month.



Our news

All news

Media Center

Read more